相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M. O'Malley et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
V Makker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Ana Oaknin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype
Megan A. Clarke et al.
JAMA ONCOLOGY (2022)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial
Ana Oaknin et al.
JAMA ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker et al.
LANCET ONCOLOGY (2019)
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
Megan A. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
Yoland Catherine Antill et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Zibing Wang et al.
ONCOIMMUNOLOGY (2017)
Endometrial cancer: Not your grandmother's cancer
Jessica N. McAlpine et al.
CANCER (2016)
Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions
Y. Louise Wan et al.
GYNECOLOGIC ONCOLOGY (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Multiple Testing in Group Sequential Trials Using Graphical Approaches
Willi Maurer et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2013)
Effects of conventional therapeutic interventions on the number and function of regulatory T cells
Mario Roselli et al.
ONCOIMMUNOLOGY (2013)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
